Home / Leaderboard / Catalio Capital Management, LP
Catalio Capital Management, LP
George Petrocheilos · Asset Manager · Multi-Strategy
Catalio Capital Management, LP is a multi-strategy investment firm founded in 2020 by George Petrocheilos and R. Jacob Vogelstein. Headquartered in New York, the firm focuses on investing in breakthrough biomedical technology and innovative healthcare companies worldwide. Catalio was established as a spinout from Camden Partners and has rapidly grown to manage billions in assets across private equity, private credit, and public equity strategies. The firm is distinguished by its extensive network of world-renowned scientist-entrepreneurs who serve as venture partners, assisting with rigorous scientific due diligence and providing proprietary deal flow. Catalio invests across the full lifecycle of healthcare companies, supporting ventures from their earliest scientific inception through to late-stage growth and public offerings.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +46.3% |
| YTD return | +18.6% |
| Sharpe ratio | 3.09 |
| Win rate | 70% |
| AUM | $0.8B |
| Inception | Oct 1, 2025 |
| Updated | Sep 22, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $0.8B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.cataliocapital.com |
Current Holdings
Updated on Sep 22, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| HTFL | Heartflow, Inc. Common Stock | 29.0% | +46.0% |
| LLY | Eli Lilly and Company | 7.4% | +42.0% |
| GPCR | Structure Therapeutics Inc. American Depositary Shares | 6.9% | +41.7% |
| BBIO | BridgeBio Pharma Inc | 5.9% | +29.5% |
| ISRG | Intuitive Surgical Inc | 4.8% | -8.2% |
| SNDX | Syndax Pharmaceuticals Inc | 4.4% | +16.0% |
| NTRA | Natera Inc | 4.3% | +141.9% |
| ABBV | AbbVie Inc | 4.1% | +12.2% |
| ASND | Ascendis Pharma AS | 3.7% | +15.9% |
| DNTH | Dianthus Therapeutics Inc. | 3.6% | +151.1% |
| CYTK | Cytokinetics Inc | 3.5% | +19.4% |
| REGN | Regeneron Pharmaceuticals Inc | 3.2% | +34.2% |
| EXAS | EXACT Sciences Corporation | 3.1% | +85.9% |
| BSX | Boston Scientific Corp | 2.9% | -52.9% |
| RNA | Avidity Biosciences Inc | 2.4% | -78.6% |
| ABVX | Abivax SA American Depositary Shares | 2.3% | +19.3% |
| SLNO | Soleno Therapeutics Inc | 2.2% | -1.1% |
| PHAT | Phathom Pharmaceuticals Inc | 2.1% | -37.0% |
| ADPT | Adaptive Biotechnologies Corp | 2.1% | -60.5% |
| IRON | Disc Medicine Inc. | 1.9% | +2.1% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Jan 23, 2026 | SELL | REGN | 3.5% → 3.2% |
| Jan 23, 2026 | BUY | BSX | 2.4% → 2.9% |
| Jan 23, 2026 | SELL | SNDX | 4.5% → 4.1% |
| Jan 23, 2026 | BUY | ASND | 3.6% → 3.7% |
| Jan 23, 2026 | BUY | HTFL | 17.6% → 29.9% |
Investment Style Analysis
Catalio Capital Management, LP is widely recognized for employing a Multi-Strategy strategy. As of Sep 22, 2026, the firm oversees approximately $0.8B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Health Information Services sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Jan 23, Catalio Capital Management, LP made a significant move by reducing the position in REGN. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Catalio's investment philosophy is centered on backing transformative healthcare companies led by serial scientist-entrepreneurs with deep technical expertise. The firm leverages its unique platform, which integrates a vast network of academic and clinical experts, to identify and validate high-impact innovations in drug discovery, medical devices, diagnostics, and data science. By operating across the capital structure and throughout a company's lifecycle, Catalio aims to address capital scarcity in the life sciences sector and accelerate the commercialization of breakthroughs that improve patient outcomes while generating meaningful returns for its investors.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Catalio Capital Management, LP.
Similar Investment Style
Based on Multi-Strategy.
- Sandoz Family Office SA — Marc Duc · 3M -6.3%
- BB Gestão de Recursos - Distribuidora de Títulos e Valores Mobiliários S.A. — Denísio Liberato · 3M +7.9%
- Wolverine Trading, LLC — Robert Bellick · 3M +5.5%
- Amundi Asset Management US, Inc. — Marco Pirondini · 3M -0.7%
Frequently asked questions
How is the simulated portfolio for Catalio Capital Management, LP constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Catalio Capital Management, LP's largest holding?
As of the latest filing, Catalio Capital Management, LP's top position is Heartflow, Inc. Common Stock (HTFL), representing 29.0% of the portfolio. This reflects a high-conviction bet by the institution.
What is Catalio Capital Management, LP's historical performance and risk profile?
Our simulation indicates a total return of +46.3% with a win rate of 70%. Notably, the portfolio maintains a Sharpe Ratio of 3.09, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Catalio Capital Management, LP primarily invest in?
Catalio Capital Management, LP has a strong preference for the Biotechnology sector, which makes up 44.3% of their disclosed assets. The portfolio also has exposure to Health Information Services, indicating a specific thematic focus.
Is Catalio Capital Management, LP's portfolio concentrated or diversified?
Catalio Capital Management, LP runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 43.3% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Catalio Capital Management, LP performed in 2026?
Our AI-simulated model portfolio for Catalio Capital Management, LP tracks a Year-to-Date (YTD) return of +18.6%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does George Petrocheilos manage Catalio Capital Management, LP directly?
Yes, George Petrocheilos serves as the key portfolio manager for Catalio Capital Management, LP, overseeing the investment strategy and final capital allocation decisions.